A Search Service for Abbreviation / Long Form

■ 検索結果 - 略語 : uPA

検索条件:
検索語 : uPA
検索方法 : 完全一致
主な研究分野:

結果:  
該当略語: 2
(何れかを選択して該当結果を表示)

(出現頻度降順)
略語: uPA
出現頻度: 4393
対応する展開形の数: 37

表示設定:
[1ページの件数]
ページ移動
/ ページ
展開形 No. 展開形 主な研究分野 共起略語 PubMed/MEDLINE情報 (発表年, 題目)
urokinase-type plasminogen activator
ウロキナーゼ型プラスミノーゲン活性化因子
(4085 回)
Neoplasms
新生物, 腫瘍
(953 回)
PAI-1 (659 回)
tPA (625 回)
uPAR (507 回)
1983 Glucocorticoids inhibit plasminogen activator production by endothelial cells.
urokinase-type PA
(226 回)
Cell Biology
細胞生物学
(34 回)
PA (111 回)
tPA (108 回)
PAI-1 (62 回)
1985 Effect of dimethyl sulfoxide on human carcinoma cells, inhibition of plasminogen activator synthesis, change in cell morphology, and alteration of response to cholera toxin.
urokinase PA
(25 回)
Neurology
神経学, 神経内科学
(4 回)
tPA (19 回)
PA (13 回)
PAs (9 回)
1989 Fibrinolytic activity and localization of plasminogen activator in bovine vitreous body and aqueous humor.
urokinase-type plasminogen
(15 回)
Neoplasms
新生物, 腫瘍
(6 回)
BD-d (2 回)
ECM (2 回)
tPA (2 回)
1993 Cytokine activation of human macro- and microvessel-derived endothelial cells.
urokinase-type activator
(7 回)
Medicine
医学, 医薬
(2 回)
PLG (3 回)
tPA (3 回)
uPAR (2 回)
2003 Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein.
pro-urokinase
(血栓溶解薬) プロウロキナーゼ
(2 回)
Vascular Diseases
血管病, 血管疾患, 血管性疾患
(2 回)
FSAP (2 回)
FVII (2 回)
AF (1 回)
2008 Factor VII-activating protease (FSAP): vascular functions and role in atherosclerosis.
urinary PA
(2 回)
Urology
泌尿器科学
(1 回)
PA (1 回)
PAI-2 (1 回)
PAI1 (1 回)
1995 Diversity and modulation of plasminogen activator activity in human prostate carcinoma cell lines.
urokinase Plg activator
(2 回)
Biochemistry
生化学, 生物化学
(1 回)
tPA (2 回)
actMMP-9 (1 回)
Ann-II (1 回)
2001 Neuritogenesis and the nerve growth factor-induced differentiation of PC-12 cells requires annexin II-mediated plasmin generation.
Although plasminogen activator
(1 回)
Complementary Therapies
補完医療, 補完療法
(1 回)
CRC (1 回)
EMT (1 回)
MMPs (1 回)
2019 Carnosine Suppresses Human Colorectal Cell Migration and Intravasation by Regulating EMT and MMP Expression.
10  anti-uPAR monoclonal antibody and proteolytically inactive urokinase
(1 回)
Allergy and Immunology
アレルギー・免疫
(1 回)
HUVECs (1 回)
uPAR (1 回)
2011 Participation of the urokinase-type plasminogen activator receptor (uPAR) in neutrophil transendothelial migration.
11  endogenous plasminogen activator
(1 回)
Science
科学
(1 回)
--- 1999 Activation of proMMP-9 by a plasmin/MMP-3 cascade in a tumor cell model. Regulation by tissue inhibitors of metalloproteinases.
12  particular plasminogen activator
(1 回)
Neoplasms
新生物, 腫瘍
(1 回)
--- 1994 [Prognostic value of urokinase-type plasminogen activator and 2 inhibitors PAI-1 and PAI-2 in breast cancer].
13  ubiquitous plasminogen by cell-derived urokinase-type
(1 回)
Pathology
病理学, 病態学
(1 回)
uPAR (1 回)
1994 Plasminogen activation in healing human wounds.
14  unique PA strains
(1 回)
Cell Biology
細胞生物学
(1 回)
CF (1 回)
ePA (1 回)
2020 Cystic Fibrosis Patients Infected With Epidemic Pseudomonas aeruginosa Strains Have Unique Microbial Communities.
15  up-regulated plasminogen activator
(1 回)
Cell Biology
細胞生物学
(1 回)
GBM (1 回)
MMPs (1 回)
2020 A role for caveola-forming proteins caveolin-1 and CAVIN1 in the pro-invasive response of glioblastoma to osmotic and hydrostatic pressure.
16  uPA on cell surface urokinase
(1 回)
Biochemistry
生化学, 生物化学
(1 回)
uPAR (1 回)
1992 Occupancy of the cancer cell urokinase receptor (uPAR): effects of acid elution and exogenous uPA on cell surface urokinase (uPA).
17  uPA using AssayMax human urokinase
(1 回)
Biochemistry
生化学, 生物化学
(1 回)
EBV-EA (1 回)
TPA (1 回)
2012 Synthesis and docking studies of novel antitumor benzimidazoles.
18  uPAR and produce urokinase
(1 回)
Metabolism
代謝, 代謝作用, 新陳代謝, 物質代謝
(1 回)
ALP (1 回)
AP-1 (1 回)
KO (1 回)
2007 Urokinase plasminogen activator receptor affects bone homeostasis by regulating osteoblast and osteoclast function.
19  uPAR and urokinase
(1 回)
Biology
生物学
(1 回)
uPAR (1 回)
2020 Urokinase receptor regulates nerve regeneration through its interaction with alpha5beta1-integrin.
20  uPAR binding to its proteolytic ligand, urokinase
(1 回)
Neoplasms
新生物, 腫瘍
(1 回)
rt-TA (1 回)
uPAR (1 回)
2007 A doxycycline-inducible urokinase receptor (uPAR) upregulates uPAR activities including resistance to anoikis in human prostate cancer cell lines.
21  uPAR but undetectable levels of urokinase
(1 回)
Cell Biology
細胞生物学
(1 回)
CK18 (1 回)
uPAR (1 回)
1994 Induction of cell migration by pro-urokinase binding to its receptor: possible mechanism for signal transduction in human epithelial cells.
22  uPAR in complex with both urokinase
(1 回)
Molecular Biology
分子生物学
(1 回)
uPAR (1 回)
2008 Crystal structures of two human vitronectin, urokinase and urokinase receptor complexes.
23  uPAR mRNAs and a beta-globin reporter mRNA containing the ARE
(1 回)
Cell Biology
細胞生物学
(1 回)
AREs (1 回)
MK2 (1 回)
2003 Stabilization of urokinase and urokinase receptor mRNAs by HuR is linked to its cytoplasmic accumulation induced by activated mitogen-activated protein kinase-activated protein kinase 2.
24  uPAR primary ligand is the serine protease urokinase
(1 回)
GPI (1 回)
2022 Modulation of Cellular Function by the Urokinase Receptor Signalling: A Mechanistic View.
25  uPAR purified from the ascitic fluid has no bound ligand
(1 回)
Medicine
医学, 医薬
(1 回)
--- 1993 A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer.
26  uPAR, whether this interaction alone is critical to urokinase
(1 回)
Cell Biology
細胞生物学
(1 回)
uPAR (1 回)
2008 Signaling through urokinase and urokinase receptor in lung cancer cells requires interactions with beta1 integrins.
27  upregulated, whereas Vimentin, N-cadherin, Plasminogen Activator, Urokinase
(1 回)
Biotechnology
生物工学, 生命工学
(1 回)
AQP5 (1 回)
EMT (1 回)
MMP (1 回)
2018 Anti-cancer effect of Aquaporin 5 silencing in colorectal cancer cells in association with inhibition of Wnt/beta-catenin pathway.
28  upstream regions of the human urokinase
(1 回)
Hematology
血液学
(1 回)
JNK (1 回)
MAPK (1 回)
MP (1 回)
2004 MAPK and JNK transduction pathways can phosphorylate Sp1 to activate the uPA minimal promoter element and endogenous gene transcription.
29  uridylyl phosphate adenosine
(1 回)
Bioengineering

(1 回)
ATF7 (1 回)
lncRNA (1 回)
PCAT18 (1 回)
2021 lncRNA prostate cancer-associated transcript 18 upregulates activating transcription factor 7 to prevent metastasis of triple-negative breast cancer via sponging miR-103a-3p.
30  urinary plasminogen activator or urokinase
(1 回)
Neoplasms
新生物, 腫瘍
(1 回)
ruPAR (1 回)
uPAR (1 回)
2002 Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo.
31  urinary-type
(1 回)
Dentistry
歯学
(1 回)
--- 2010 Urokinase and its receptor in follicular and inflammatory cysts of the jaws.
32  Urokinase Activation Plasminogen
(1 回)
Medicine
医学, 医薬
(1 回)
ER (1 回)
PgR (1 回)
2018 Correlation of Serum Levels of Urokinase Activation Plasminogen (uPA) and Its Inhibitor (PAI-1) with Hormonal and HER-2 Status in the Early Invasive Breast Cancer.
33  urokinase protein
(1 回)
Neoplasms
新生物, 腫瘍
(1 回)
aFGF (1 回)
bFGF (1 回)
ELISA (1 回)
1998 Autocrine self-elimination of cultured ovarian cancer cells by tumour necrosis factor alpha (TNF-alpha).
34  urokinase-type plasminogen activation system including urokinase
(1 回)
Pharmacy
薬学
(1 回)
GFD (1 回)
2019 Designing tracers for PET imaging of the urokinase-type plasminogen activator receptor from a cyclic uPA-derived peptide: first in vitro evaluations.
35  urotype PA
(1 回)
Dentistry
歯学
(1 回)
HGF (1 回)
PA (1 回)
PAI-1 (1 回)
1999 Enhancement of LPS-stimulated plasminogen activator production in aged gingival fibroblasts.
36  used as a therapeutic inhibitor of urokinase
(1 回)
Biochemistry
生化学, 生物化学
(1 回)
alpha 1-PI (1 回)
CT (1 回)
PAI-1 (1 回)
1990 Plasminogen activator inhibitor 2 (PAI-2) is not inactivated by exposure to oxidants which can be released from activated neutrophils.
37  Using a CDCP1-biased probe, we identify urokinase
(1 回)
Biology
生物学
(1 回)
CDCP1 (1 回)
sbABP (1 回)
2021 Substrate-biased activity-based probes identify proteases that cleave receptor CDCP1.